PT  - JOURNAL ARTICLE
AU  - David C. Lobb
AU  - Heather Doviak
AU  - Gregory L. Brower
AU  - Eva Romito
AU  - Jason W. O’Neill
AU  - Stephen Smith
AU  - James A. Shuman
AU  - Parker D. Freels
AU  - Kia N. Zellars
AU  - Lisa A. Freeburg
AU  - Aarif Y. Khakoo
AU  - TaeWeon Lee
AU  - Francis G. Spinale
TI  - Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post–Myocardial Infarction Remodeling
AID  - 10.1124/jpet.120.000047
DP  - 2020 Nov 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 296--307
VI  - 375
IP  - 2
4099  - http://jpet.aspetjournals.org/content/375/2/296.short
4100  - http://jpet.aspetjournals.org/content/375/2/296.full
SO  - J Pharmacol Exp Ther2020 Nov 01; 375
AB  - Infarct expansion can occur after myocardial infarction (MI), which leads to adverse left ventricular (LV) remodeling and failure. An imbalance between matrix metalloproteinase (MMP) induction and tissue inhibitors of MMPs (TIMPs) can accelerate this process. Past studies have shown different biologic effects of TIMP-3, which may depend upon specific domains within the TIMP-3 molecule. This study tested the hypothesis that differential effects of direct myocardial injections of either a full-length recombinant TIMP-3 (F-TIMP-3) or a truncated form encompassing the N-terminal region (N-TIMP-3) could be identified post-MI. MI was induced in pigs that were randomized for MI injections (30 mg) and received targeted injections within the MI region of F-TIMP-3 (n = 8), N-TIMP-3 (n = 9), or saline injection (MI-only, n = 11). At 14 days post-MI, LV ejection fraction fell post-MI but remained higher in both TIMP-3 groups. Tumor necrosis factor and interleukin-10 mRNA increased by over 10-fold in the MI-only and N-TIMP-3 groups but were reduced with F-TIMP-3 at this post-MI time point. Direct MI injection of either a full-length or truncated form of TIMP-3 is sufficient to favorably alter the course of post-MI remodeling. The functional and differential relevance of TIMP-3 domains has been established in vivo since the TIMP-3 constructs demonstrated different MMP/cytokine expression profiles. These translational studies identify a unique and more specific therapeutic strategy to alter the course of LV remodeling and dysfunction after MI.SIGNIFICANCE STATEMENT Using different formulations of tissue inhibitor of matrix metalloproteinase-3 (TIMP-3), when injected into the myocardial infarction (MI) region, slowed the progression of indices of left ventricular (LV) failure, suggesting that the N terminus of TIMP-3 is sufficient to attenuate early adverse functional events post-MI. Injections of full-length recombinant TIMP-3, but not of the N-terminal region of TIMP-3, reduced relative indices of inflammation at the mRNA level, suggesting that the C-terminal region affects other biological pathways. These unique proof-of-concept studies demonstrate the feasibility of using recombinant small molecules to selectively interrupt adverse LV remodeling post-MI.